有证据表明,监管和市场力量正在推动生物类似药的采用
Janice Jhang1, Troyen A Brennan2
1Janice Jhang (janicejhang@g.harvard.edu), Harvard University, Cambridge, Massachusetts.
Health affairs (Project Hope)
|November 4, 2024
概括
美国生物仿制药市场最初令人失望,现在正在勃发展,提供了降低生物药物成本的机会. 政策干预可以进一步加速生物类似药的采用和可负担性.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 生物技术是生物技术.
背景情况:
- 美国生物类似药市场自成立以来表现不佳,引发了对其未来的担忧.
- 生物仿制药提供了一个关键的途径来管理不断上升的生物药物支出,并提高药物可获得性.
- 了解不同药物类别和金融利益相关方的市场动态至关重要.
研究的目的:
- 评估美国生物类似药市场的演变和当前状况.
- 确定有助于市场表现和未来可行性的因素.
- 通过案例研究来研究政策和市场动态.
主要方法:
- 审查药物类别的区别和金融利益相关者的参与.
- 对批准后生物类药物市场最近证据的分析.
- 对阿达利穆马布生物类似剂的进入和市场影响的案例研究分析.
主要成果:
- 尽管面临着早期的挑战,但美国生物类似药市场正在显示成熟和增长的迹象.
- 对阿达利穆马布生物类似药的引入说明了不断变化的市场和政策趋势.
- 有证据表明,在批准后,生物相似物种的景观正在勃发展.
结论:
- 美国生物类似药市场正在积极发展,成功的迹象越来越多.
- 政策制定者可以利用监管和支付策略,进一步推动生物类似药的普及.
- 加快生物类似药的采用是控制医疗保健成本和改善患者获得基本药物的关键.
相关概念视频
Drug Control Governance: Regulatory Bodies and Their Impact
144
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
144
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Bioequivalence: Overview
926
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
926
Pharmacovigilance
776
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
776
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K


